| 1 |
35435472 | A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. | 2022 May |
1 |
| 2 |
32218813 | Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. | 2020 Apr |
1 |
| 3 |
27739325 | A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. | 2017 Feb |
1 |
| 4 |
28356425 | Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. | 2017 Aug 1 |
1 |
| 5 |
27488020 | Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report. | 2016 Aug 3 |
1 |
| 6 |
25818403 | A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. | 2015 Jun |
2 |
| 7 |
23474559 | BRCA-associated pancreatic cancer: the evolving management. | 2013 Mar 10 |
2 |
| 8 |
22291137 | Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. | 2012 Mar 15 |
1 |
| 9 |
22101337 | Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. | 2011 Dec 1 |
1 |